RxDoctor Payments Data

Rahool Karnik, MD

Cardiovascular Disease · Phoenix, AZNPI 1932183563

Payments from drug & device makers

$14,769in general payments, 2019–2025

Across 383 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Novartis$1K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$776
  • Amgen$701
  • plus $7K from 38 others

What the payments were for

  • Travel & lodging$8526%
  • Food & beverage$13,70093%
  • Education$2171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,769 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$628,146
Medicare patients
936
Services billed
4,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban656$717,567
Repatha SureclickEvolocumab182$141,333
CamzyosMavacamten13$107,032
EntrestoSacubitril/Valsartan97$102,649
XareltoRivaroxaban64$84,670
BrilintaTicagrelor71$59,681
FarxigaDapagliflozin Propanediol40$30,132
VascepaIcosapent Ethyl25$19,217
LivaloPitavastatin Calcium22$13,607
Atorvastatin Calcium1,013$10,836
Rosuvastatin Calcium550$10,250
VerquvoVericiguat12$7,861
Bisoprolol Fumarate201$6,224
Metoprolol Succinate441$6,129
Losartan Potassium546$5,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$384$717,567656 claims
E.r. Squibb & Sons, L.L.C.Camzyos$487$107,03213 claims
NovartisEntresto$1,118$102,64997 claims
AstraZenecaBrilinta, Farxiga$366$89,813111 claims
Johnson & JohnsonXarelto$181$84,67064 claims
Kowa Pharmaceuticals America, Inc.Livalo$42$13,60722 claims
MerckVerquvo$499$7,86112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →